Physician profile
James A Mutcherson
NPI 1922191956
$667.29
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $414.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $194.57 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $170.20 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $93.55 | 2022 | |
| Biocryst US Sales Co., LLC | $51.20 | 2021 | |
| Amgen INC. | $46.58 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.49 | 2021 | |
| Genzyme Corporation | $33.38 | 2022 | |
| Pfizer INC. | $25.36 | 2021 | |
| Hikma Pharmaceuticals USA | $16.96 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mutcherson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.